| Variable |
HR |
95% CI |
p-value |
| Age* |
0.976 |
0.912 - 1.041 |
0.459 |
| Gender (vs. Male) |
1.125 |
0.133 - 9.532 |
0.914 |
| Stage III (vs Stage I/II) |
1.974 |
0.344 - 11.340 |
0.446 |
| EUS Tumor Length* |
0.436 |
0.922 - 1.379 |
0.242 |
| Histopathology (vs SqCC) |
1.128 |
0.022 – 8.826 |
0.589 |
| Surgery (vs. No surgery) |
0.380 |
0.091 - 1.582 |
0.184 |
| % SUV change* |
0.526 |
0.028 - 9.977 |
0.669 |
| Post-CRT SUV* |
1.401 |
1.061 - 1.850 |
0.017 |
* - continuous variable; HR – hazard ratio; CI – confidence interval; CRT –
chemoradiotherapy; SUV – standard uptake value; EUS – endoscopic ultrasound;
SqCC – squamous cell carcinoma |
